Las Vegas, NV -- (SBWIRE) -- 12/20/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: ReneSola Ltd. (ADR) (NYSE:SOL), Astrotech Corp (NASDAQ:ASTC), Athersys, Inc. (NASDAQ:ATHX), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)
ReneSola Ltd. (ADR) (NYSE:SOL) managed to keep its gain at 3.23% on below -normal volume of 2.37M shares. The stock settled at $3.20 after floating in a range of $3.13 to $3.25. Its latest price has reached market capitalization of $325.26 million. Its 52-week range has been $1.25 to $6. ReneSola Ltd (ReneSola), incorporated on March 17, 2006, is a global manufacturer of solar wafers and producer of solar power products based in the People's Republic of China. ReneSola possess a global network of suppliers and customers that includes some of the global manufacturers of solar cells and modules.
For How Long SOL will fight for Profitability? Read This Trend Analysis report
Astrotech Corp (NASDAQ:ASTC) traded up on a volume of 2.31 million, higher than its standard daily volume. Shares have gained 20.62% to $3.10. Over the last twelve months, the stock has gained 20.62% and faced a worst price of $0.61. Astrotech Corporation (Astrotech) is a commercial aerospace company. The Company's focused on providing world-class facilities and related support services necessary for the preparation of satellites and payloads; providing satellite and payload processing and integration service and support; designing and fabricating equipment and hardware for launch activities; Supplying propellant and associated services for spacecraft; managing launch logistics and support, and commercializing space-based technologies.
For How Long ASTC’s Gloss will Attract Investors? Find out via this report
Athersys, Inc. (NASDAQ:ATHX) settled 2.91% higher at $2.12 on above-normal volume of 2.21M shares during the last trading day. The stock has its 12-month high at $2.42 and 52-week low price was $0.99. It traded in a range of $2.02 to $2.15 during the last trading day. Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials.
Why Should Investors Buy ATHX After the Recent Fall? Just Go Here and Find Out
In the last trading session, Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) was down on high volume, trading at a volume of 2.17M versus its average daily volume of 1.87 million shares. At $2.17, the stock has attained market capitalization of 291.53 million. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping.
Why Should Investors Buy NAVB After the Recent Fall? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)